Latest news and press releases about Connect Biopharma Holdings Limited (CNTB): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical company dedicated to discovering and advancing immune modulators. Its primary objective is to develop treatments for serious autoimmune diseases and various inflammatory conditions. The company's lead investigational therapy is CBP-201, an anti-interleukin-4 receptor alpha antibody.
Price
| Price | $1.24 |
| Market Cap | $78M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 2.31 |
| EV / EBITDA | -2.19 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -132.16% |
| Return on Invested Capital | -135.74% |
| Return on Assets | -98.94% |
| Gross Margin | 100.00% |
| Operating Margin | -90740.62% |
| Net Margin | -86687.50% |
Related companies: ARTV · CNTX · IFRX · IMA · KLRS · MGX · OVID
Explore sector: Healthcare · Biotechnology
More sections of CNTB: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks